https://prabadinews.com/
  • October 10, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for.

administrator

Related Articles